Traditional Chinese medicine composition for treating metabolism-related fatty liver disease and application thereof

Through the Chinese medicine composition of Ganzao Ning No. Ⅱ, water decoction extract of jujube, yam and other ingredients, the treatment problems of metabolic-related fatty liver disease are solved, and the weight, liver steatosis and inflammation are significantly controlled, and liver steatosis and inflammation are protected, and liver function is protected. A low-cost, non-toxic side effects treatment plan.

CN118948975APending Publication Date: 2024-11-15SHANGHAI ZHUANGCHENG HEALTH IND GRP CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411198064.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Currently, there are lack of effective drugs or therapies for the treatment of metabolic-related fatty liver diseases. The existing Chinese medicine compound preparations are effective in the treatment of precancerous liver lesions and liver cancer, but they have poor control of metabolic-related fatty liver diseases.

Method used

Ganzaoling No. II, a Chinese medicine composition composed of jujube, yam, Buddha's hand, corn squid, lotus leaves, ginseng leaves and hawthorn, is made into decoction or other dosage forms through decoction extract, which is used to treat metabolic-related fatty liver disease. , regulates weight, liver steatosis, inflammation and blood sugar levels.

Benefits of technology

It significantly inhibits weight gain and liver steatosis caused by a high-fat diet, reduces liver tissue inflammation, protects liver function, controls blood sugar levels, and provides a low-cost, non-toxic side effects treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948975A_ABST
    Figure CN118948975A_ABST
Patent Text Reader

Abstract

The invention discloses a traditional Chinese medicine composition Ganzizhenning II which is prepared from the following components in parts by weight: 1-20 parts of Chinese dates, 1-20 parts of Chinese yams, 1-10 parts of fingered citron, 1-9 parts of corn stigma, 1-9 parts of lotus leaves, 1-15 parts of ginseng leaves and 1-20 parts of haws. The traditional Chinese medicine composition Ganzigning II provided by the invention has a good curative effect on metabolism-related fatty liver diseases. As a medicinal and edible traditional Chinese medicine compound, the traditional Chinese medicine composition is definite in curative effect, free of toxic and side effects and low in cost, and has good clinical application and popularization prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a traditional Chinese medicine composition for treating metabolism-related fatty liver disease and application thereof. Background Art

[0002] Metabolic-associated fatty liver disease (MAFLD) is a metabolic stress liver disease that is closely related to insulin resistance and genetic susceptibility, including simple hepatic steatosis, steatohepatitis (MASH), MASH-associated cirrhosis, and hepatocellular carcinoma. Currently, no effective drugs or therapies have been approved for NAFLD, and efforts to control complications of the disease are far from satisfactory. Therefore, there is an urgent need to screen promising therapeutic strategies for this disease.

[0003] The patent application with the publication number CN102600382A discloses a Chinese medicine compound preparation for strengthening the spleen and soothing the liver, which is prepared by weight of 1-20 parts of jujube, 1-20 parts of yam, 1-10 parts of hawthorn, 1-10 parts of bergamot, 1-10 parts of corn silk, and 1-10 parts of lotus leaf as raw materials. The invention also discloses a preparation method of the Chinese medicine compound preparation. The Chinese medicine compound preparation of the present invention has the effect of strengthening the spleen and soothing the liver. After many years of clinical application and pharmacological research, it has been confirmed that it can be used for the treatment of precancerous lesions of liver cancer including viral hepatitis, cirrhosis, and liver fibrosis, as well as for delaying and preventing the development of precancerous lesions of liver cancer to liver cancer, and has the advantages of definite efficacy, no toxic side effects, and low cost. Summary of the invention

[0004] The purpose of the present invention is to provide a Chinese medicine composition Ganzaoning II for treating metabolism-related fatty liver disease.

[0005] Another object of the present invention is to provide a use of the traditional Chinese medicine composition in the preparation of a medicament for treating metabolism-related fatty liver disease.

[0006] In order to achieve the above object, the technical solution adopted by the present invention is as follows:

[0007] The first aspect of the present invention provides a Chinese medicine composition Gan Zaoning II, which is made of the following components in parts by weight: 1-20 parts of jujube, 1-20 parts of yam, 1-10 parts of bergamot, 1-9 parts of corn silk, 1-9 parts of lotus leaf, 1-15 parts of ginseng leaf, and 1-20 parts of hawthorn.

[0008] Preferably, the Chinese medicine composition is made of the following components in parts by weight: 10-20 parts of jujube, 6-20 parts of yam, 6-10 parts of bergamot, 5-9 parts of corn silk, 5-9 parts of lotus leaf, 5-12 parts of ginseng leaf, and 10-20 parts of hawthorn.

[0009] Most preferably, the Chinese medicine composition is made of the following components in parts by weight: 10 parts of jujube, 10 parts of yam, 6 parts of bergamot, 5 parts of corn silk, 5 parts of lotus leaf, 5 parts of ginseng leaf, and 10 parts of hawthorn.

[0010] Most preferably, the Chinese medicine composition is made of the following components in parts by weight: 15 parts of jujube, 6 parts of yam, 6 parts of bergamot, 9 parts of corn silk, 6 parts of lotus leaf, 12 parts of ginseng leaf, and 15 parts of hawthorn.

[0011] Most preferably, the Chinese medicine composition is made of the following components in parts by weight: 20 parts of jujube, 20 parts of yam, 1 part of bergamot, 9 parts of corn silk, 9 parts of lotus leaves, 9 parts of ginseng leaves, and 20 parts of hawthorn.

[0012] Most preferably, the Chinese medicine composition is made of the following components in parts by weight: 1 part of jujube, 1 part of yam, 10 parts of bergamot, 1 part of corn silk, 1 part of lotus leaf, 1 part of ginseng leaf, and 1 part of hawthorn.

[0013] In the present invention, ginseng leaf and bergamot are used as the main ingredients for strengthening the spleen and soothing the liver, yam and jujube are used as the secondary ingredients for strengthening the spleen, hawthorn and corn silk are used as the auxiliary ingredients for promoting digestion and diuresis, and lotus leaf is used as the messenger for promoting the generation of clear yang.

[0014] The properties, flavors, meridians and functions of the Chinese medicine raw materials of the present invention are as follows:

[0015] Jujube: sweet, warm. Enter the spleen, stomach, and heart meridians. Effects: replenish qi, nourish blood, and calm the mind.

[0016] Chinese Yam: sweet, neutral. Enters the spleen, lung, and kidney meridians. Efficacy: replenishes qi and nourishes yin, tonifies the spleen, lungs, and kidneys, astringes semen, and stops leukorrhea.

[0017] Citron: pungent, bitter, sour, warm. Enters the liver, spleen, stomach, and lung meridians. Efficacy: soothes the liver and regulates qi, harmonizes the stomach and relieves pain, dries dampness and resolves phlegm.

[0018] Corn silk: sweet, neutral. Enters the bladder, liver, and gallbladder meridians. Effects: promotes diuresis and reduces swelling, removes dampness and reduces jaundice.

[0019] Lotus leaf: bitter, neutral. Enters the liver, spleen, and stomach meridians. Efficacy: clears away heat and dampness, promotes the development of clear yang, cools blood and stops bleeding.

[0020] Ginseng leaf: bitter, sweet, cold; enters the lung and stomach meridians. Effects: replenishes qi and calms the mind, strengthens the spleen and stomach, relieves summer heat and clears away heat, promotes the production of body fluids and quenches thirst.

[0021] Hawthorn: sour, sweet, slightly warm. Enters the spleen, stomach, and liver meridians. Efficacy: helps digestion and invigorates the stomach, promotes qi and dissipates blood stasis, removes turbidity and reduces fat.

[0022] The second aspect of the present invention provides a use of the traditional Chinese medicine composition in the preparation of a medicament for treating metabolism-related fatty liver disease.

[0023] The third aspect of the present invention provides a pharmaceutical preparation made from the traditional Chinese medicine composition.

[0024] The dosage form of the pharmaceutical preparation is decoction pieces, capsules, tablets, granules, pills, microcapsule preparations, microsphere preparations, nano preparations, etc.

[0025] Due to the adoption of the above technical solution, the present invention has the following advantages and beneficial effects:

[0026] The Chinese medicine composition provided by the present invention has a good therapeutic effect on metabolic-related fatty liver disease. As a Chinese medicine compound for both medicinal and edible purposes, it not only has a definite therapeutic effect, but also has no toxic side effects and low cost, and has a good clinical application and promotion prospect.

[0027] The present invention feeds rats with a high-fat diet and simultaneously treats them with the Chinese medicine composition of the present invention, and it is found that: the high-fat diet can increase the body weight of rats, while the Chinese medicine composition of the present invention (Gan Zaoning II) can significantly inhibit the weight gain caused by the high-fat diet; the high-fat diet can increase the liver-to-weight ratio of rats and cause fatty degeneration of the liver, while the Chinese medicine composition of the present invention (Gan Zaoning II) can significantly reduce the liver-to-weight ratio and alleviate fatty degeneration of the liver; the high-fat diet can cause mild liver tissue inflammation and damage liver cells in rats, while the Chinese medicine composition of the present invention (Gan Zaoning II) significantly alleviates inflammation and liver cell damage; the high-fat diet can affect the liver function level of rats, while the Chinese medicine composition of the present invention (Gan Zaoning II) can regulate these levels and protect the liver; the Chinese medicine composition of the present invention (Gan Zaoning II) can effectively control the blood sugar level of rats.

[0028] The present invention proves through animal experiments that the Chinese medicine composition (Gan Zaoning II) can improve metabolic-related fatty liver disease caused by a high-fat diet, control the patient's weight, reduce liver fatty degeneration, reduce inflammation, protect liver tissue, and control blood sugar levels. For patients who eat a high-fat diet for a long time, it has good use value, can reduce the incidence of metabolic-related fatty liver disease, and reduce medical costs.

[0029] The Chinese medicine composition (Gan Zaoning II) of the present invention is made of jujube, yam, bergamot, corn silk, lotus leaf, ginseng leaf and hawthorn. Compared with the patent application with publication number CN102600382A, ginseng leaf is added. After the composition is changed, the Chinese medicine composition (Gan Zaoning II) of the present invention has good therapeutic effects in controlling body weight, reducing liver fatty degeneration, relieving inflammation and liver cell damage, improving liver function, and controlling blood sugar in the treatment of metabolism-related fatty liver disease.

[0030] The raw materials used in the Chinese medicine compound preparation of the present invention are cheap, and it can be used as both medicine and food, and is safe to eat. After many years of clinical application, it has a good therapeutic effect on the treatment of metabolism-related fatty liver disease. In view of the huge number of patients who need to use the preparation, the Chinese medicine compound preparation provided by the present invention has a good application prospect. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 It is a schematic diagram showing the effect of the Chinese medicinal composition (Gan Zaoning II) of the present invention on the weight gain of rats caused by a high-fat diet.

[0032] Figure 2 It is a schematic diagram of the effect of the Chinese medicinal composition (Gan Zaoning II) of the present invention on the final body weight of rats fed a high-fat diet (Note: *P<0.05, **P<0.01).

[0033] Figure 3 It is a schematic diagram of the effect of the Chinese medicine composition (Gan Zaoning II) of the present invention on the liver weight ratio of rats fed a high-fat diet (Note: ***p<0.001).

[0034] Figure 4 It is a schematic diagram of the effect of the Chinese medicine composition (Gan Zaoning II) of the present invention on the macroscopic morphology of the liver of rats fed a high-fat diet.

[0035] Figure 5 It is a schematic diagram of the effect of the Chinese medicine composition (Gan Zaoning II) of the present invention on the Oil Red O staining pathological morphology of liver tissue in rats fed a high-fat diet.

[0036] Figure 6 It is a schematic diagram of the effect of the Chinese medicine composition (Gan Zaoning II) of the present invention on the pathological morphology of liver tissue stained by H&E in rats fed a high-fat diet.

[0037] Figure 7 It is a schematic diagram of the effect of the Chinese medicine composition (Gan Zaoning II) of the present invention on the serum biochemical indexes of rats fed a high-fat diet (Note: *P<0.05, **P<0.01). DETAILED DESCRIPTION

[0038] In order to explain the present invention more clearly, the present invention is further described below in conjunction with preferred embodiments. It should be understood by those skilled in the art that the following specific description is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.

[0039] Example 1

[0040] Weigh 90g of jujube, 90g of yam, 54g of bergamot, 45g of corn silk, 45g of lotus leaf, 45g of ginseng leaf, and 90g of hawthorn, decoct and extract with water for 3 times (4000mL, 1 hour; 3000mL, 1 hour; 3000mL, 1 hour), combine the extracts, concentrate, dry, and crush. This extract can be directly packaged and taken orally.

[0041] Example 2

[0042] Weigh 200g of jujube, 200g of yam, 10g of bergamot, 90g of corn silk, 90g of lotus leaf, 90g of ginseng leaf, and 200g of hawthorn, decoct and extract with water for 3 times (4000mL, 1 hour; 3000mL, 1 hour; 3000mL, 1 hour), combine the extracts, concentrate, dry, and crush. This extract can be directly packaged and taken orally.

[0043] Example 3

[0044] Weigh 10g of jujube, 10g of yam, 100g of bergamot, 10g of corn silk, 10g of lotus leaf, 10g of ginseng leaf, and 10g of hawthorn, decoct and extract with water for 3 times (4000mL, 1 hour; 3000mL, 1 hour; 3000mL, 1 hour), combine the extracts, concentrate, dry, and crush. This extract can be directly packaged and taken orally.

[0045] Example 4

[0046] Preparation of granules: Add 300 g of dextrin to 150 g of the extract prepared according to the method of Example 1, mix well, add an appropriate amount of 60% ethanol to make a soft material, sieve through a 24-mesh sieve to granulate, dry at 50°C for 2 hours, sieve the dried granules through a 30-mesh sieve, and package to obtain.

[0047] Example 5

[0048] Tablet production:

[0049]

[0050] 1000 tablets were prepared according to the above ratio.

[0051] Example 6

[0052] Study on the effect of Chinese herbal medicine combination on improving metabolic-related fatty liver disease in rats induced by high-fat diet

[0053] 1. Materials and methods

[0054] (1) Experimental animals and feed

[0055] Forty male SD rats (6 weeks old) were provided by the Experimental Animal Center of the Naval Medical University of the Chinese People's Liberation Army. They were kept in an SPF animal experimental center with a 12-hour day and night cycle and a constant temperature of 18-20°C. Rats were free to eat and drink. All rats were adaptively raised for one week, and the experiment was carried out after they adapted to the living environment. 60% high-fat model feed (TP23400) was purchased from Nantong Trofi Feed Technology Co., Ltd. 10% low-fat control feed (TP23402) was purchased from Nantong Trofi Feed Technology Co., Ltd.

[0056] (2) Preparation of main reagents

[0057] The preparation method of the Chinese medicine composition (Ganzaoning II) water decoction comprises the following steps:

[0058] Hawthorn, corn silk, lotus leaf, bergamot, yam, and jujube were purchased from Wujiang Shanghai Cai Tongdetang Chinese Medicine Pieces Co., Ltd. with batch numbers: 23092604, 23120414, 24050909, 24051607, 23112412, and 23122012; ginseng leaf was purchased from Shanghai Kangqiao Chinese Medicine Pieces Co., Ltd. with batch number: 230510.

[0059] Weigh 90g of hawthorn, 45g of corn silk, 45g of lotus leaf, 54g of bergamot, 90g of yam, 90g of jujube, and 45g of ginseng leaf, decoct and extract with water for 3 times (4000mL, 1 hour; 3000mL, 1 hour; 3000mL, 1 hour), combine the extracts, and concentrate. The low-concentration Ganzaoning II decoction is concentrated to contain 1g / mL of crude drug, and the high-concentration Ganzaoning II decoction is concentrated to contain 3g / mL of crude drug.

[0060] (3) Model preparation and group administration

[0061] 1. Weigh 40 SD rats, number them, and record their weight.

[0062] 2. Then the rats were randomly divided into 4 groups, namely A. LFD group; B. HFD group; C. GZN-L group; D. GZN-H group; there were 10 rats in each group. There was no significant difference in the body weight of rats in each group before the experiment.

[0063] 3. Feeding and medication

[0064] LFD group: fed with 10% low-fat control diet and given sterile drinking water by gavage (4.59 ml / kg / d);

[0065] HFD group: fed with 60% high-fat model diet and given sterile drinking water by gavage (4.59 ml / kg / d);

[0066] GZN-L group: fed with 60% high-fat model feed, and given low-concentration (containing crude drug 1g / mL) Ganzaoning II decoction by gavage (4.59ml / kg / d);

[0067] GZN-H group: fed with 60% high-fat model feed, and given high-concentration (containing crude drug 3g / mL) Ganzaoning II decoction by gavage (4.59ml / kg / d);

[0068] The drug was administered once a day for 16 weeks. The animals in each group were housed in separate cages, and their body weights were recorded weekly.

[0069] 4. Specimen collection: After the last administration, fasting but not water for 12 hours, anesthetized with 3% sodium pentobarbital (40 mg / kg), weighed and measured body length, blood was collected from the abdominal aorta, placed in a blood collection tube, and allowed to stand at 4°C for 4 hours, then centrifuged at 3000g for 15 minutes at 4°C, and the upper serum was collected and stored in a -80°C refrigerator for serum biochemical testing. Rat livers were separated, weighed, and the appearance and color of the livers were observed. The left lateral lobe of the rat liver was cut and fixed in a 12% neutral formaldehyde solution for 48 hours for pathological testing, and some were stored in a -80°C refrigerator for subsequent experiments.

[0070] (II) Experimental results

[0071] Figure 1 The figure is a schematic diagram of the effect of the Chinese medicine composition (Gan Zaoning II) of the present invention on the weight gain of rats caused by a high-fat diet. The weight change trend reflects that a high-fat diet increases the weight gain rate of rats, while low-dose and high-dose Gan Zaoning II both delay the weight gain of rats caused by a high-fat diet. This shows that Gan Zaoning II has a good therapeutic effect on controlling the weight gain caused by a high-fat diet.

[0072] Figure 2 The figure is a schematic diagram of the effect of the Chinese medicine composition (Ganzaoning II) of the present invention on the final body weight of rats fed a high-fat diet (Note: *P<0.05, **P<0.01). After 16 weeks of administration, compared with the normal diet group, the high-fat diet significantly increased the body weight of the rats, and the difference was statistically significant (P<0.05), while the low-dose and high-dose Ganzaoning II significantly restricted the weight gain of the rats, and the difference was statistically significant (P<0.01). This shows that Ganzaoning II has a good therapeutic effect on controlling the weight gain caused by a high-fat diet.

[0073] Figure 3This is a schematic diagram of the effect of the Chinese medicine composition (Ganzaoning II) of the present invention on the liver weight ratio of rats fed a high-fat diet (Note: ***p<0.001). Comparing the ratio of liver weight to body weight of rats, there was no statistically significant difference in the liver weight ratio between the high-fat diet group (HFD group) and the low-fat diet group (LFD group), while the low-dose and high-dose GZN-L group and GZN-H group significantly reduced the liver weight ratio of rats (P<0.001). A high-fat diet can cause fat deposition in hepatocytes and increase liver weight. This result proves that Ganzaoning II can significantly improve the liver weight ratio, indicating its improvement effect on liver fat deposition.

[0074] Figure 4 This is a schematic diagram of the effect of the Chinese medicine composition (Ganzaoning II) of the present invention on the macroscopic morphology of the liver of rats fed a high-fat diet. Macroscopic observation of the rat liver showed that the high-fat diet caused significant fatty degeneration in the rat liver, while the low-dose and high-dose GZN-L group and GZN-H group significantly improved the fatty degeneration of the rat liver caused by the high-fat diet. The color of the liver with fatty degeneration will turn white. In this result, the color of the rat liver treated with Ganzaoning II was significantly redder than that of the high-fat diet group, indicating that Ganzaoning II can improve fatty degeneration of the liver.

[0075] Figure 5 The figure is a schematic diagram showing the effect of the Chinese medicine composition (Ganzaoning II) of the present invention on the Oil Red O staining pathological morphology of liver tissue in rats fed a high-fat diet. Oil Red O staining of liver tissue confirmed that the Chinese medicine composition (Ganzaoning II) of the present invention reduced the lipid content of liver tissue in a dose-dependent manner, indicating that Ganzaoning II can reduce fat deposition in rat liver tissue caused by a high-fat diet. The results confirmed from the pathological morphology that Ganzaoning II can inhibit liver fat deposition caused by a high-fat diet and has a good therapeutic effect on metabolic-related fatty liver disease.

[0076] Figure 6 This is a schematic diagram of the effect of the Chinese medicine composition (Gan Zaoning II) of the present invention on the pathological morphology of H&E staining of liver tissue in rats fed a high-fat diet. H&E staining of liver tissue shows that the Chinese medicine composition (Gan Zaoning II) of the present invention reduces the inflammatory infiltration and ballooning degeneration of rat liver tissue in a dose-dependent manner, indicating that the Chinese medicine composition (Gan Zaoning II) of the present invention has the effect of reducing liver tissue inflammation and liver cell damage in rats caused by a high-fat diet. This result confirms from the pathological morphology that Gan Zaoning II can reduce the inflammatory damage of liver cells caused by a high-fat diet, and has a good therapeutic effect on controlling the further development of metabolic-related fatty liver disease.

[0077] Figure 7This is a schematic diagram of the effect of the Chinese medicine composition (Ganzaoning II) of the present invention on the serum biochemical indicators of rats fed a high-fat diet (Note: *P<0.05, **P<0.01). The results of serum biochemical tests showed that a high-fat diet increased the levels of AST and ALP in serum (P<0.05), while the high-dose GZN-H group partially reversed the increase of the two (P<0.05, P<0.01), indicating that Ganzaoning can alleviate the liver damage caused by a high-fat diet in rats and protect their liver function; the low-dose and high-dose GZN-L and GZN-H groups both reduced the GSP levels of rats fed a high-fat diet (P<0.05 and P<0.01), indicating that the Chinese medicine composition (Ganzaoning II) of the present invention can better control blood sugar in rats. The results of laboratory biochemical indicators confirmed that Ganzaoning II can reduce the inflammatory damage of hepatocytes caused by a high-fat diet, improve liver function, and control blood sugar, and has a good effect on preventing the further development of metabolic-related fatty liver disease.

[0078] The effects of the Chinese medicine composition in the patent application with publication number CN102600382A in animal experiments are: 1. reducing the amount of liver collagen fiber deposition in the process of rat liver cirrhosis induced by diethylnitrosamine (DEN); 2. reducing the positive expression of C-myc and IGF-II proteins in the process of rat liver cancer induction. The Chinese medicine composition of the present invention has the following new effects: 1. delaying the weight gain of rats caused by a high-fat diet; 2. reducing the liver-to-weight ratio of rats and reducing liver fatty degeneration; 3. significantly inhibiting liver fatty degeneration of rats caused by a high-fat diet; 4. reducing liver tissue inflammation and liver cell damage in rats caused by a high-fat diet; 5. controlling blood sugar in rats.

[0079] Typical Case 1

[0080] Chen, male, born in 1973, Shanghai. Outpatient medical record number: 269163. The patient was diagnosed with fatty liver by B-ultrasound in 2005, and had a history of hepatitis B for more than 20 years. Serum biochemistry on 2020-10-25 showed: ALT 186U / L, AST 159U / L, γ-GT 130U / L, TC24.5mmol / L, TG 6.94mmol / L, blood glucose 7.92mmol / L. On 2020-11-03, he was treated in the outpatient department of Changhai Hospital and given Ganzaoning II. The prescription was: 12g ginseng leaf, 15g raw hawthorn, 9g corn silk, 6g lotus leaf, 6g bergamot, 6g yam, 15g jujube; decocted in water, one dose per day, divided into morning and evening; a total of 28 doses. 2020-12-25 serum biochemistry recheck: ALT47 U / L, AST 50U / L, blood sugar 7.28mmol / L, γ-GT, TC, TG all returned to normal. Continue to treat with Ganzaoning II, prescription: 12g ginseng leaf, 15g raw hawthorn, 9g corn silk, 6g lotus leaf, 6g bergamot, 6g yam, 15g jujube; decoction, one dose per day, morning and evening. 2021-1-18 serum biochemistry recheck: no abnormality. So stop the medication, regular recheck.

[0081] Typical Case 2

[0082] Han, male, born in 1976, Shanghai. Outpatient medical record number: 304727. The patient had B-ultrasound on 2021-6-7: fatty liver; serum biochemistry: ALT 79U / L, AST 63U / L, uric acid 541μmol / L, TC 7.57mmol / L, TG 5.87mmol / L, LDL-C4.72mmol / L. On 2021-6-8, he was treated in the outpatient department of Changhai Hospital and given Ganzaoning II. The prescription: 12g ginseng leaf, 15g raw hawthorn, 9g corn silk, 6g lotus leaf, 6g bergamot, 6g yam, 15g jujube; decocted in water, one dose per day, divided into morning and evening. 2021-8-5 serum biochemistry recheck: ALT 64U / L, AST 32U / L, TC 6.89mmol / L, TG 2.83mmol / L, LDL-C 4.6mmol / L, uric acid returned to normal. 2021-08-11 follow-up: still feel easy to fatigue recently; dark red tongue, thin yellow fur, dark lips and red eyes, deep and thin pulse; continue to give Ganzaoning II plus or minus treatment, prescription: ginseng leaf 12g, raw hawthorn 15g, corn silk 9g, lotus leaf 6g, bergamot 6g, yam 6g, jujube 15g; decoction, one dose per day, morning and evening. The patient took the medicine intermittently during the period. 2022-6-28 serum biochemistry recheck: basically normal; liver B-ultrasound showed no obvious abnormalities. So stop the medication and check regularly.

[0083] Typical Case 3

[0084] Fu, male, born in 1962, Shanghai. Outpatient medical record number: 354585. 2022-1-4 physical examination B-ultrasound: mild fatty liver. Serum biochemistry: ALT 61.1U / L, AST 46.8U / L, TC 6.89mmol / L, TG 2.83mmol / L, LDL-C4.6mmol / L. 2022-3-2 went to Changhai Hospital for outpatient treatment and was treated with Ganzaoning II plus or minus treatment. Prescription: 12g ginseng leaves, 15g raw hawthorn, 9g corn silk, 6g lotus leaves, 6g bergamot, 6g yam, 15g jujube; decocted in water, one dose per day, divided into morning and evening. 2022-6-8 follow-up: During the self-report period, he insisted on taking the medicine, and his fatigue improved; his tongue was tender and red without coating, his lips were purple, his face was dark red, his eyes were red, and his pulse was thin and stringy. Ganzaoning II was given for continued treatment. The prescription was: 12g of ginseng leaves, 15g of raw hawthorn, 9g of corn silk, 6g of lotus leaves, 6g of bergamot, 6g of yam, and 15g of jujube. Decoction was taken in water, one dose per day, divided into morning and evening. B-ultrasound was re-examined on July 12, 2023: no obvious abnormality was found. Serum biochemistry was basically normal. The medication was then stopped and regular re-examination was conducted.

[0085] The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment, it is not used to limit the present invention. Any technician familiar with this patent can make some changes or modify the technical contents suggested above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the solution of the present invention.

Claims

1. A Chinese medicine composition, characterized in that: The invention is prepared from the following components in parts by weight: 1-20 parts of jujube, 1-20 parts of yam, 1-10 parts of bergamot, 1-9 parts of corn silk, 1-9 parts of lotus leaf, 1-15 parts of ginseng leaf and 1-20 parts of hawthorn.

2. The Chinese medicine composition according to claim 1, characterized in that: The traditional Chinese medicine composition is prepared from the following components in parts by weight: 10-20 parts of jujube, 6-20 parts of yam, 6-10 parts of bergamot, 5-9 parts of corn silk, 5-9 parts of lotus leaf, 5-12 parts of ginseng leaf and 10-20 parts of hawthorn.

3. The Chinese medicine composition according to claim 1, characterized in that The traditional Chinese medicine composition is prepared from the following components in parts by weight: 10 parts of jujube, 10 parts of yam, 6 parts of bergamot, 5 parts of corn silk, 5 parts of lotus leaf, 5 parts of ginseng leaf and 10 parts of hawthorn.

4. The Chinese medicine composition according to claim 1, characterized in that: The traditional Chinese medicine composition is prepared from the following components in parts by weight: 15 parts of jujube, 6 parts of yam, 6 parts of bergamot, 9 parts of corn silk, 6 parts of lotus leaf, 12 parts of ginseng leaf and 15 parts of hawthorn.

5. The Chinese medicine composition according to claim 1, characterized in that: The traditional Chinese medicine composition is prepared from the following components in parts by weight: 20 parts of jujube, 20 parts of yam, 1 part of bergamot, 9 parts of corn silk, 9 parts of lotus leaf, 9 parts of ginseng leaf and 20 parts of hawthorn.

6. The Chinese medicine composition according to claim 1, characterized in that: The traditional Chinese medicine composition is prepared from the following components in parts by weight: 1 part of jujube, 1 part of yam, 10 parts of bergamot, 1 part of corn silk, 1 part of lotus leaf, 1 part of ginseng leaf and 1 part of hawthorn.

7. Use of the traditional Chinese medicine composition according to any one of claims 1 to 6 in the preparation of a medicament for treating metabolism-related fatty liver disease.

8. A pharmaceutical preparation made from the Chinese medicine composition according to any one of claims 1 to 6.

9. The pharmaceutical preparation according to claim 8, characterized in that The dosage form of the pharmaceutical preparation is decoction pieces, capsules, tablets, granules, pills, microcapsule preparations, microsphere preparations, and nano preparations.

Citation Information

Patent Citations

  • Traditional Chinese compound preparation for strengthening spleen and soothing liver as well as application thereof

    CN102600382A